Amedisys Research and Development Expenses 2010-2023 | AMED

Amedisys research and development expenses from 2010 to 2023. Research and development expenses can be defined as an expense arising from studies and product development processes.
Amedisys Annual Research and Development Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Amedisys Quarterly Research and Development Expenses
(Millions of US $)
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $3.128B $2.236B
Amedisys Inc. provides home health and hospice services throughout the U.S. to the growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, congestive heart failure, orthopedics, complex wound care, geriatric surgical recovery, balance retraining, behavioral health and stroke recovery, as well as various rehabilitative programs. It provides hospice services to patients using an interdisciplinary care team comprising a physician, nurses, home health aides, social workers, therapists, dieticians, volunteers, counselors, chaplains and bereavement coordinators, when required. The company depends on reimbursement from Medicare (for chronic care) for a significant portion of its revenues on account of the age demographics of its patient base (average age of 81).
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $17.436B 10.55
Quest Diagnostics (DGX) United States $15.460B 15.98
DaVita (DVA) United States $12.016B 14.93
Encompass Health (EHC) United States $8.745B 22.38
Chemed (CHE) United States $8.614B 26.70
Elanco Animal Health (ELAN) United States $8.436B 21.89
Option Care Health (OPCH) United States $5.209B 19.72
RadNet (RDNT) United States $4.191B 87.28
LifeStance Health (LFST) United States $2.825B 0.00
Astrana Health (ASTH) United States $2.242B 30.32
Addus HomeCare (ADUS) United States $1.798B 25.73
U.S Physical Therapy (USPH) United States $1.603B 42.90
Pennant (PNTG) United States $0.667B 35.25
Aveanna Healthcare Holdings (AVAH) United States $0.494B 0.00
Atai Life Sciences (ATAI) Germany $0.320B 0.00
Daxor (DXR) United States $0.045B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.027B 0.00
ATI Physical Therapy (ATIP) United States $0.022B 0.00
Psychemedics (PMD) United States $0.015B 0.00
Ontrak (OTRK) United States $0.014B 0.00
Novo Integrated Sciences (NVOS) United States $0.011B 0.00
IMAC Holdings (BACK) United States $0.004B 0.00